{"id":"long-acting-cabotegravir-injection","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Injection site reactions (pain, induration, erythema)"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Pyrexia"},{"rate":"5-10","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cabotegravir binds to the active site of HIV integrase and inhibits the strand transfer step of viral integration into the host genome. The long-acting injectable formulation provides sustained plasma concentrations over weeks to months, enabling less frequent dosing compared to daily oral antiretrovirals. This mechanism maintains suppression of HIV replication and reduces viral load in treated individuals.","oneSentence":"Cabotegravir is an integrase strand transfer inhibitor (INSTI) that blocks HIV integrase, preventing the virus from inserting its genetic material into human DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:34:16.071Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naive and treatment-experienced adults (long-acting injectable formulation for maintenance therapy)"}]},"trialDetails":[{"nctId":"NCT02938520","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-27","conditions":"HIV Infections","enrollment":631},{"nctId":"NCT02720094","phase":"PHASE2, PHASE3","title":"Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-12-19","conditions":"HIV Infections","enrollment":4570},{"nctId":"NCT07199335","phase":"PHASE4","title":"Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-02-24","conditions":"HIV, Substance Use Disorder (SUD), Injection Drug Use","enrollment":100},{"nctId":"NCT05917509","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2023-07-06","conditions":"HIV Infections","enrollment":171},{"nctId":"NCT06694805","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1","status":"RECRUITING","sponsor":"ViiV Healthcare","startDate":"2024-12-02","conditions":"HIV Infections","enrollment":332},{"nctId":"NCT05986084","phase":"PHASE4","title":"Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2023-11-30","conditions":"Pre-Exposure Prophylaxis (PrEP), Breast Feeding","enrollment":500},{"nctId":"NCT04979728","phase":"","title":"HIV Outpatient Monitoring Evaluation Through Self-collection of Dried Blood Spots","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2021-05-27","conditions":"HIV Treatment, HIV Prevention","enrollment":150},{"nctId":"NCT05991622","phase":"PHASE2","title":"Combined Injectable Treatment for HIV and OUD","status":"WITHDRAWN","sponsor":"Rhode Island Hospital","startDate":"2022-04-01","conditions":"Human Immunodeficiency Virus, Opioid Use Disorder","enrollment":""},{"nctId":"NCT06854029","phase":"PHASE4","title":"NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings","status":"NOT_YET_RECRUITING","sponsor":"Duke University","startDate":"2026-06","conditions":"HIV Infections, Opioid Use Disorder, Incarceration; Lens","enrollment":300},{"nctId":"NCT05514509","phase":"PHASE4","title":"A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2022-10-28","conditions":"HIV Infections","enrollment":370},{"nctId":"NCT06411223","phase":"PHASE2","title":"Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2024-08-01","conditions":"Hiv","enrollment":50},{"nctId":"NCT03497676","phase":"PHASE1, PHASE2","title":"More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-03","conditions":"HIV Infections","enrollment":168},{"nctId":"NCT07370649","phase":"","title":"Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study","status":"NOT_YET_RECRUITING","sponsor":"Pomeranian Medical University Szczecin","startDate":"2026-02-01","conditions":"Human Immunodeficiency Virus (HIV)-1 Infection, HIV-1 Subtype A6 Infection, HIV-1 Subtype B Infection","enrollment":250},{"nctId":"NCT07346508","phase":"NA","title":"Project SPEED - Streamlined Protocol for Early Engagement and Delivery of HIV Prevention With Long-acting Injectable Cabotegravir: A Nurse-driven Protocol","status":"NOT_YET_RECRUITING","sponsor":"KC Care Health Center","startDate":"2026-04-01","conditions":"HIV (Human Immunodeficiency Virus)","enrollment":250},{"nctId":"NCT06657885","phase":"PHASE2","title":"CAbotégravir LENacapavir DUal Long Acting","status":"WITHDRAWN","sponsor":"Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba","startDate":"2025-01-15","conditions":"HIV1 Infection, Multi-treated Patients Who Have Received Multiple Lines of Antiretroviral Treatment, CABOTEGRAVIR","enrollment":""},{"nctId":"NCT02951052","phase":"PHASE3","title":"Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":618},{"nctId":"NCT05799339","phase":"","title":"Optimizing CAB-LA as PrEP for Women Who Inject Drugs","status":"COMPLETED","sponsor":"Alexis Roth","startDate":"2022-01-13","conditions":"HIV Infections, Opioid Use, Trauma, Psychological","enrollment":144},{"nctId":"NCT06134362","phase":"PHASE3","title":"Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)","status":"RECRUITING","sponsor":"ViiV Healthcare","startDate":"2024-05-14","conditions":"HIV Infections","enrollment":3508},{"nctId":"NCT05418868","phase":"PHASE1","title":"A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants","status":"RECRUITING","sponsor":"ViiV Healthcare","startDate":"2022-06-14","conditions":"HIV Infections","enrollment":214},{"nctId":"NCT05374525","phase":"PHASE4","title":"A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2022-05-18","conditions":"HIV Infections","enrollment":287},{"nctId":"NCT06451341","phase":"","title":"IMplementation of CAB+RPV LA for People With HIV in Non-Metropolitan Areas","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2024-07-01","conditions":"HIV","enrollment":55},{"nctId":"NCT06970223","phase":"PHASE1","title":"A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2025-04-22","conditions":"HIV Infections","enrollment":65},{"nctId":"NCT06741397","phase":"PHASE2","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2024-12-20","conditions":"HIV Infections","enrollment":229},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT06145854","phase":"","title":"Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Midway Specialty Care Center","startDate":"2024-01-02","conditions":"Hiv","enrollment":100},{"nctId":"NCT03164564","phase":"PHASE3","title":"Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-11-07","conditions":"HIV Infections","enrollment":3224},{"nctId":"NCT03635788","phase":"PHASE3","title":"The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-03-28","conditions":"HIV Infections","enrollment":456},{"nctId":"NCT03299049","phase":"PHASE3","title":"Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2017-10-27","conditions":"HIV Infections","enrollment":1049},{"nctId":"NCT07131826","phase":"","title":"The Quality of Life and Viral Control Effect of AIDS Patients After Long-acting Injection of Cabotegravir and Rilpivirine","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Clinical Trial Center","startDate":"2025-08-15","conditions":"Viral Control, Quality of Life, Cabotegravir","enrollment":200},{"nctId":"NCT06336434","phase":"PHASE1, PHASE2","title":"CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-05-01","conditions":"HIV-1-infection, Pregnancy, Postpartum","enrollment":""},{"nctId":"NCT05867212","phase":"","title":"Implementation and Delivery of Cabotegravir Long Acting Injection for PrEP in a Community Pharmacy Setting.","status":"COMPLETED","sponsor":"Kelley-Ross & Associates, Inc.","startDate":"2023-05-13","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT06474364","phase":"PHASE4","title":"HIV Prevention and Care Interventions for Youth in Uganda","status":"RECRUITING","sponsor":"MU-JHU CARE","startDate":"2024-08-05","conditions":"HIV","enrollment":600},{"nctId":"NCT06868641","phase":"NA","title":"The TAIL-PrEP Study","status":"NOT_YET_RECRUITING","sponsor":"Columbia University","startDate":"2026-01","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT06786520","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2025-01-17","conditions":"HIV Infections","enrollment":69},{"nctId":"NCT05601128","phase":"PHASE3","title":"A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA","status":"COMPLETED","sponsor":"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)","startDate":"2023-01-01","conditions":"HIV-1-infection, HIV Infections, HIV I Infection","enrollment":12},{"nctId":"NCT05660980","phase":"PHASE1, PHASE2","title":"Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-01-24","conditions":"HIV-1-infection","enrollment":90},{"nctId":"NCT03739996","phase":"PHASE2","title":"Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-31","conditions":"HIV Infections","enrollment":75},{"nctId":"NCT04692077","phase":"PHASE2","title":"Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-02-19","conditions":"HIV Infections","enrollment":9},{"nctId":"NCT05663580","phase":"","title":"Cohort Study of HIV-positive People, Treated With Long Acting Antiretroviral Therapy","status":"RECRUITING","sponsor":"Castagna Antonella","startDate":"2022-07-17","conditions":"HIV Infections","enrollment":1500},{"nctId":"NCT05044962","phase":"NA","title":"Kuwa Free! - Live Free!","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-11-26","conditions":"HIV Infections, Contraception, Drug-drug Interaction","enrollment":700},{"nctId":"NCT06158126","phase":"PHASE4","title":"UNCPM 22314 - Pregnancy, Infant and Maternal Health Outcomes Study","status":"RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2024-04-17","conditions":"Pre-exposure Prophylaxis, HIV Prevention, Pregnancy Related","enrollment":621},{"nctId":"NCT06424964","phase":"","title":"Use of Long-Acting Injectable Cabotegravir/Rilpivirine for the Treatment of HIV in Belgium","status":"RECRUITING","sponsor":"Belgian Research on AIDS and HIV Consortium","startDate":"2025-01-13","conditions":"Human Immunodeficiency Virus","enrollment":600},{"nctId":"NCT06807736","phase":"","title":"PrEPared to Choose (PtC) is an Implementation Study of the Delivery of Cabotegravir Long-acting, an Injectable Pre-exposure Prophylaxis (PrEP) Option for HIV Prevention. Injectable PrEP Will be Offered Alongside Oral and Vaginal Ring PrEP From Within a Real-world Context in Cape Town, South Africa.","status":"RECRUITING","sponsor":"Desmond Tutu HIV Foundation","startDate":"2024-02-13","conditions":"HIV Infection, Sexual and Reproductive Health","enrollment":1800},{"nctId":"NCT04973254","phase":"NA","title":"Improving Treatment and Retention Adherence in Nontraditional Settings","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2022-02-23","conditions":"HIV Infections","enrollment":25},{"nctId":"NCT06704204","phase":"","title":"Long-acting Injectable Antiretroviral Treatment to Improve HIV Treatment Among Justice-involved Persons Being Released to the Community","status":"NOT_YET_RECRUITING","sponsor":"The Miriam Hospital","startDate":"2025-02","conditions":"HIV","enrollment":20},{"nctId":"NCT04824131","phase":"PHASE2","title":"Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-11-04","conditions":"HIV Infections","enrollment":55},{"nctId":"NCT05896748","phase":"PHASE3","title":"Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2022-11-08","conditions":"Human Immunodeficiency Virus Type 1 (HIV-1)","enrollment":94},{"nctId":"NCT05835635","phase":"","title":"Switch From Oral Therapy to Long-acting Injectable Cabotegravir + Rilpivirine","status":"NOT_YET_RECRUITING","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2025-05-01","conditions":"Patient Satisfaction, Patient Preference, Quality of Life","enrollment":50},{"nctId":"NCT06635421","phase":"","title":"The Expand Study-Pharmacist Administered Long Acting Cabotegravir + Rilpivirine to Expand Access for People With HIV","status":"NOT_YET_RECRUITING","sponsor":"MetroHealth Medical Center","startDate":"2024-11-01","conditions":"HIV I Infection","enrollment":164},{"nctId":"NCT05515770","phase":"PHASE3","title":"The Implementation of Pre-exposure Prophylaxis of Injectable Cabotegravir","status":"RECRUITING","sponsor":"Evandro Chagas National Institute of Infectious Disease","startDate":"2022-09-20","conditions":"HIV Infections","enrollment":1200},{"nctId":"NCT03856580","phase":"NA","title":"Long-acting Biomedical HIV Prevention in Transgender Women","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2020-10-23","conditions":"HIV Prevention, Transgender Women","enrollment":19},{"nctId":"NCT05546242","phase":"PHASE3","title":"Improving HIV-1 Control in Africa with Long Acting Antiretrovirals","status":"ACTIVE_NOT_RECRUITING","sponsor":"MRC/UVRI and LSHTM Uganda Research Unit","startDate":"2022-12-08","conditions":"HIV-1-infection","enrollment":540},{"nctId":"NCT05096949","phase":"NA","title":"Implementing Cabenuva in Arkansas HIV Programs","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2022-03-07","conditions":"HIV-1-infection, Medication Adherence, Satisfaction, Patient","enrollment":1},{"nctId":"NCT06507059","phase":"PHASE3","title":"Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting Antiretrovirals","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2024-07-19","conditions":"HIV-1-infection, Non-Adherence, Medication","enrollment":40},{"nctId":"NCT06518408","phase":"","title":"A Real-life Study of the Use of Cabotegravir Plus Rilpivirine Long-acting in ART-experienced Pre-treated People With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital Virgen de las Nieves","startDate":"2023-06-01","conditions":"Human Immunodeficiency Virus","enrollment":287},{"nctId":"NCT06138600","phase":"PHASE3","title":"Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Witwatersrand, South Africa","startDate":"2023-11-01","conditions":"HIV Infections","enrollment":200},{"nctId":"NCT02120352","phase":"PHASE2","title":"A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-04-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":309},{"nctId":"NCT03639311","phase":"PHASE2","title":"Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2018-09-24","conditions":"HIV Infections","enrollment":97},{"nctId":"NCT04542070","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-11-09","conditions":"HIV Infections","enrollment":687},{"nctId":"NCT06405464","phase":"","title":"Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures","status":"RECRUITING","sponsor":"University of Zurich","startDate":"2022-03-01","conditions":"HIV Infections","enrollment":600},{"nctId":"NCT06403865","phase":"","title":"Patient-Reported Outcomes in Real-life of Cabotegravir and Rilpivirine","status":"NOT_YET_RECRUITING","sponsor":"University Paris 7 - Denis Diderot","startDate":"2024-05","conditions":"Quality of Life","enrollment":280},{"nctId":"NCT05154747","phase":"PHASE3","title":"Long-Acting Treatment in Adolescents (LATA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University College, London","startDate":"2023-06-22","conditions":"Hiv, HIV Infections, HIV-1-infection","enrollment":476},{"nctId":"NCT04371380","phase":"PHASE1","title":"Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-09-16","conditions":"HIV Infections","enrollment":15},{"nctId":"NCT06250504","phase":"PHASE3","title":"Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCT","status":"RECRUITING","sponsor":"Africa Health Research Institute","startDate":"2024-02-27","conditions":"HIV Infections","enrollment":2000},{"nctId":"NCT04399551","phase":"PHASE3","title":"A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-09-28","conditions":"HIV Infections","enrollment":437},{"nctId":"NCT06319105","phase":"","title":"PathToScale: An Implementation Evaluation","status":"RECRUITING","sponsor":"Georgetown University","startDate":"2024-03-26","conditions":"Oral Pre-exposure Prophylaxis (PrEP), Long-acting Injectable Cabotegravir for PrEP","enrollment":9900},{"nctId":"NCT06273943","phase":"PHASE3","title":"Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2024-04-01","conditions":"Prevention","enrollment":322},{"nctId":"NCT05949203","phase":"","title":"Oregon PrEP at Home Study","status":"UNKNOWN","sponsor":"Oregon Health and Science University","startDate":"2023-12-01","conditions":"HIV/AIDS","enrollment":125},{"nctId":"NCT04484337","phase":"PHASE1","title":"Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-07-31","conditions":"HIV Infections","enrollment":138},{"nctId":"NCT05152953","phase":"","title":"Preparing for Pharmacy-based Delivery of Long-acting Injectable Antiretroviral Therapy (LAI-ART)","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2022-06-08","conditions":"Hiv","enrollment":63},{"nctId":"NCT06133686","phase":"PHASE3","title":"Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan Africa","status":"NOT_YET_RECRUITING","sponsor":"MRC/UVRI and LSHTM Uganda Research Unit","startDate":"2024-04-01","conditions":"HIV","enrollment":400},{"nctId":"NCT05896761","phase":"PHASE3","title":"A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2021-10-28","conditions":"Human Immunodeficiency Virus Type 1 (HIV-1)","enrollment":118},{"nctId":"NCT04001803","phase":"PHASE3","title":"Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2019-07-08","conditions":"HIV Infections","enrollment":115},{"nctId":"NCT02178800","phase":"PHASE2","title":"Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-02","conditions":"HIV Infections","enrollment":199},{"nctId":"NCT03422172","phase":"PHASE1","title":"A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Chinese Men","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2018-04-10","conditions":"HIV Infections","enrollment":48},{"nctId":"NCT02478463","phase":"PHASE1","title":"Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2017-02-27","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":19},{"nctId":"NCT02076178","phase":"PHASE2","title":"Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-03-27","conditions":"Infection, Human Immunodeficiency Virus","enrollment":127},{"nctId":"NCT02462772","phase":"PHASE2","title":"Safety and Acceptability of Cabotegravir in HIV Uninfected Women in KwaZulu-Natal, South Africa","status":"WITHDRAWN","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2015-10","conditions":"Human Immunodeficiency Virus","enrollment":""},{"nctId":"NCT01754116","phase":"PHASE1","title":"A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2013-01","conditions":"Infection, Human Immunodeficiency Virus","enrollment":43},{"nctId":"NCT01593046","phase":"PHASE1","title":"A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2012-05","conditions":"Infection, Human Immunodeficiency Virus","enrollment":43},{"nctId":"NCT01756131","phase":"PHASE1","title":"A Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intramuscular and Subcutaneous Long Acting GSK1265744 in Healthy Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2010-09","conditions":"Infections, Human Immunodeficiency Virus and Herpesviridae","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Long-acting Cabotegravir injection","genericName":"Long-acting Cabotegravir injection","companyName":"MU-JHU CARE","companyId":"mu-jhu-care","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cabotegravir is an integrase strand transfer inhibitor (INSTI) that blocks HIV integrase, preventing the virus from inserting its genetic material into human DNA. Used for HIV-1 infection in treatment-naive and treatment-experienced adults (long-acting injectable formulation for maintenance therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}